ECTRIMS 2022: Research Insights from Day One

Подписаться 3,7 тыс.

50% 1

Brett Drummond (Co-founder, MStranslate) and Dr Travis Stiles (CEO, Novoron Bioscience) reflect on some of the key research outcomes presented throughout the first day of ECTRIMS 2022, the world's largest multiple sclerosis (MS) research conference. Topics covered include paediatric MS, remyelination, biomarkers, autologous hematopoietic stem cell transplantation (AHSCT) and treatment dosing.
Learn more about ECTRIMS 2022 by visiting the official event website at the following link - 2022.ectrims-congress.eu
Learn more about MStranslate and follow us on our other platforms via the links below:
Website: mstranslate.com.au
Facebook: / mstranslate
Twitter: / mstranslate
Instagram: / mstranslate
LinkedIn: / mstranslate

Наука

Опубликовано:

25 окт 2022

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист

Посмотреть позже

Комментарии : 6

@thomasdumont1474 Год назад

Thank you to be there for us

@__Wanderer Год назад

microglial cell activation seems to be the target /mechanism behind tecfidera... known since 2014: paper: Strategies to increase the activity of microglia as efficient protectors of the brain against infections

@__Wanderer Год назад

wish they would also apply the same brute force methodology methods to how they found clemastine as a potential remyelinating mechanism. Essentially brute force with hundreds of drugs in petri-dishes to see which stimulates growth. Perhaps also looking at the molecular similarities between drugs that also act effectively. I believe besides clemastine there were one or two that were similar - if you could isolate the molecule responsible for enhancing growth perhaps you could tailor the drug so that is more highly concentrated to only that which is effective/ more targeted.

@samanthafoor1594 Год назад

Enjoyed these updates very much! Thank you for your commitment.

@__Wanderer Год назад

I wonder what role covid plays actually besides EBV. I was first diagnosed only 4 ish weeks after having a covid infection for 10 days or so. Never had any other symptoms before in my life and I am in my late 20s. I have seen a lot of other neurological problems related to C19 - I wonder to what extent it could potentially also act as a trigger.

@__Wanderer Год назад

I really wish it was possible for me to do HSCT. In the netherlands they are backwards - they still use the escalation scale so i have to get worse before being allowed better meds... but HSCT would be amazing and am still shocked at how slow the adoption is. Although I suppose big pharma plays a role in blocking that... Getting HSCT treatment and not having to take meds for 10-20 years sounds incredible but I guess that would hurt their bottom line.